Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEM 3454 P50 Sensory Gating in Schizophrenia
NCT00725855Phase 2Unknown
- Sponsor
- Memory Pharmaceuticals
- Start
- Aug 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of facinicline in schizophrenia, sponsored by Memory Pharmaceuticals. Status: unknown.
02
Drugs
facinicline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00725855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00725855.